CHRM3
Basic information
Region (hg38): 1:239386565-239915452
Links
Phenotypes
GenCC
Source:
- prune belly syndrome (Strong), mode of inheritance: AR
- prune belly syndrome (Supportive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Prune belly syndrome (Eagle-Barrett syndrome) | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Genitourinary; Musculoskeletal; Renal | 14797335; 15912376; 22077972; 31441039 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CHRM3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 29 | 31 | ||||
missense | 23 | 28 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 5 | |||||
Total | 0 | 0 | 26 | 32 | 8 |
Variants in CHRM3
This is a list of pathogenic ClinVar variants found in the CHRM3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-239548263-G-A | Prune belly syndrome | Uncertain significance (Jun 23, 2021) | ||
1-239907303-T-C | Benign (Nov 12, 2018) | |||
1-239907460-G-A | Likely benign (Mar 14, 2023) | |||
1-239907463-C-T | Likely benign (Dec 30, 2022) | |||
1-239907480-C-T | not specified | Uncertain significance (Feb 28, 2023) | ||
1-239907543-C-G | Uncertain significance (Oct 17, 2022) | |||
1-239907544-G-A | Likely benign (Mar 27, 2022) | |||
1-239907572-A-G | not specified | Uncertain significance (Aug 08, 2022) | ||
1-239907582-G-A | Uncertain significance (Jul 07, 2023) | |||
1-239907610-C-T | CHRM3-related disorder | Benign (Apr 15, 2023) | ||
1-239907643-C-T | CHRM3-related disorder | Likely benign (Jul 25, 2022) | ||
1-239907644-G-A | Benign (Feb 01, 2024) | |||
1-239907665-G-A | Uncertain significance (Mar 13, 2022) | |||
1-239907734-G-A | not specified | Uncertain significance (May 31, 2023) | ||
1-239907779-C-T | Prune belly syndrome | Likely benign (Jan 24, 2023) | ||
1-239907803-G-A | Prune belly syndrome | Pathogenic (Aug 04, 2020) | ||
1-239907820-T-C | Likely benign (Apr 12, 2023) | |||
1-239907835-C-T | Likely benign (Jun 15, 2018) | |||
1-239907866-T-C | Likely benign (May 22, 2023) | |||
1-239907901-A-T | Likely benign (Jun 27, 2022) | |||
1-239907964-G-C | Likely benign (Sep 01, 2023) | |||
1-239908009-T-C | Likely benign (Apr 06, 2022) | |||
1-239908042-T-G | Uncertain significance (Dec 22, 2023) | |||
1-239908132-T-C | Prune belly syndrome | Likely benign (Mar 12, 2023) | ||
1-239908253-C-T | Likely benign (Jun 14, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CHRM3 | protein_coding | protein_coding | ENST00000255380 | 1 | 528886 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.993 | 0.00747 | 125699 | 0 | 2 | 125701 | 0.00000796 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.96 | 236 | 337 | 0.700 | 0.0000197 | 3882 |
Missense in Polyphen | 25 | 98.03 | 0.25502 | 1156 | ||
Synonymous | -0.705 | 158 | 147 | 1.07 | 0.0000103 | 1184 |
Loss of Function | 3.83 | 1 | 19.0 | 0.0525 | 0.00000120 | 195 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000104 | 0.00000880 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. {ECO:0000269|PubMed:7565628}.;
- Disease
- DISEASE: Prune belly syndrome (PBS) [MIM:100100]: A syndrome characterized by thin abdominal musculature with overlying lax skin, cryptorchism, megacystis with disorganized detrusor muscle, and urinary tract abnormalities. {ECO:0000269|PubMed:22077972}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Gastric acid secretion - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);Calcium signaling pathway - Homo sapiens (human);Salivary secretion - Homo sapiens (human);Pancreatic secretion - Homo sapiens (human);Neuroactive ligand-receptor interaction - Homo sapiens (human);Cholinergic synapse - Homo sapiens (human);Taste transduction - Homo sapiens (human);Insulin secretion - Homo sapiens (human);Proton Pump Inhibitor Pathway, Pharmacodynamics;Pantoprazole Action Pathway;Rabeprazole Action Pathway;Esomeprazole Action Pathway;Omeprazole Action Pathway;Lansoprazole Action Pathway;Gastric Acid Production;Nizatidine Action Pathway;Cimetidine Action Pathway;Famotidine Action Pathway;Ranitidine Action Pathway;Betazole Action Pathway;Roxatidine acetate Action Pathway;Metiamide Action Pathway;Pirenzepine Action Pathway;GPCRs, Other;GPCRs, Class A Rhodopsin-like;Regulation of Actin Cytoskeleton;Calcium Regulation in the Cardiac Cell;Monoamine GPCRs;Signaling by GPCR;Signal Transduction;Metabolism;Muscarinic acetylcholine receptors;Acetylcholine regulates insulin secretion;Amine ligand-binding receptors;Regulation of insulin secretion;Class A/1 (Rhodopsin-like receptors);GPCR ligand binding;Integration of energy metabolism;G alpha (q) signalling events;GPCR downstream signalling
(Consensus)
Recessive Scores
- pRec
- 0.104
Intolerance Scores
- loftool
- rvis_EVS
- -0.14
- rvis_percentile_EVS
- 43.77
Haploinsufficiency Scores
- pHI
- 0.205
- hipred
- Y
- hipred_score
- 0.792
- ghis
- 0.400
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.851
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Chrm3
- Phenotype
- growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; muscle phenotype; vision/eye phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; renal/urinary system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype;
Gene ontology
- Biological process
- regulation of vascular smooth muscle contraction;cellular protein modification process;smooth muscle contraction;signal transduction;G protein-coupled receptor signaling pathway;G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger;adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway;G protein-coupled acetylcholine receptor signaling pathway;chemical synaptic transmission;synaptic transmission, cholinergic;nervous system development;cell population proliferation;positive regulation of smooth muscle contraction;saliva secretion;G protein-coupled serotonin receptor signaling pathway
- Cellular component
- plasma membrane;integral component of plasma membrane;basolateral plasma membrane;cell junction;dendrite;axon terminus;glutamatergic synapse;integral component of presynaptic membrane;integral component of postsynaptic density membrane
- Molecular function
- phosphatidylinositol phospholipase C activity;G protein-coupled receptor activity;G protein-coupled serotonin receptor activity;protein binding;G protein-coupled acetylcholine receptor activity;neurotransmitter receptor activity;signaling receptor activity;acetylcholine binding